Format

Send to

Choose Destination
Kidney Int. 2019 Feb;95(2):405-411. doi: 10.1016/j.kint.2018.09.021. Epub 2018 Dec 21.

Long-term outcome of kidney transplantation in AL amyloidosis.

Author information

1
Renal Section, Department of Medicine, Boston Medical Center, Boston, Massachusetts, USA.
2
Renal Section, Department of Medicine, Boston Medical Center, Boston, Massachusetts, USA; Amyloidosis Center, Boston University School of Medicine, Boston, Massachusetts, USA.
3
Section of Hematology and Oncology, Department of Medicine, Boston Medical Center, Boston Massachusetts, USA; Amyloidosis Center, Boston University School of Medicine, Boston, Massachusetts, USA.
4
Amyloidosis Center, Boston University School of Medicine, Boston, Massachusetts, USA; Boston University School of Public Health, Boston, Massachusetts, USA.
5
Renal Section, Department of Medicine, Boston Medical Center, Boston, Massachusetts, USA; Amyloidosis Center, Boston University School of Medicine, Boston, Massachusetts, USA. Electronic address: ahavasi@bu.edu.

Abstract

Therapies for AL amyloidosis have dramatically improved, leading to longer patient survival; however, more AL amyloidosis patients are reaching end-stage renal disease (ESRD). There are no clear guidelines regarding eligibility for kidney transplantation in patients with AL amyloidosis, and data on outcomes are limited. We evaluated the clinical and laboratory data of 49 patients who were followed in the Amyloidosis Center at Boston University and underwent kidney transplantation at a center in the United States between 1987-2017. During a median follow-up of 7.2 years (range 0-19), the median patient survival from diagnosis was 15.4 years, and from kidney transplantation was 10.5 years. One, three, and five-year graft survival were 94%, 89%, and 81%, respectively. Patients with hematologic complete response or very good partial response prior to kidney transplantation had significantly better patient survival than patients with partial response or no response, and the median time to graft loss was 10.4 years versus 5.5 years, respectively. This is the largest published series of kidney transplantation in patients with AL amyloidosis, suggesting that kidney transplantation can have a good outcome in carefully selected patients, particularly in those who have achieved a complete response or very good partial response at the time of kidney transplantation.

KEYWORDS:

AL amyloidosis; ESRD; graft survival; hematologic response; renal transplantation

PMID:
30580886
DOI:
10.1016/j.kint.2018.09.021
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center